Gemeprost
From Wikipedia, the free encyclopedia
 |
|
|
Gemeprost
|
|
| Systematic (IUPAC) name | |
| methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2- [(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]- 5-oxo-cyclopentyl]hept-2-enoate |
|
| Identifiers | |
| CAS number | |
| ATC code | G02 |
| PubChem | |
| Chemical data | |
| Formula | C23H38O5 |
| Mol. mass | 394.545 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Pessary |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
[edit] Clinical use
It is used as a treatment for obstetric bleeding. It is used with RU486 to terminate pregnancy up to 24 weeks gestation.
[edit] Side effects
Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
